Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Castle Biosciences, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.752 Joining me today are Castle's founder, president, and chief executive officer, Derek 00:00:04.752 -- 00:00:08.300 Massild, and chief financial officer, Frank Stokes. 00:00:08.300 -- 00:00:12.645 Information recorded on this call speaks only as of today, August 4, 2025. 00:00:12.645 -- 00:00:14.127 Therefore, 00:00:14.127 -- 00:00:18.733 if you are listening to the replay or reading the transcript of this call, any time-sensitive 00:00:18.733 -- 00:00:23.659 information may no longer be accurate. A recording of today's call will be available 00:00:23.659 -- 00:00:28.485 on the Investor Relations page of the company's website for approximately three weeks 00:00:28.485 -- 00:00:33.649 following the conclusion of the call. Before we begin, I would like to remind you that 00:00:33.649 -- 00:00:38.240 some of the statements made today will contain forward looking statements within the 00:00:38.240 -- 00:00:43.214 meaning of the Private Securities Litigation Reform Act of 1995. 00:00:43.214 -- 00:00:47.539 These forward-looking statements include, but are not limited to, statements about our 00:00:47.539 -- 00:00:52.884 financial outlook, TAM, intended use populations, and similar items referenced 00:00:52.884 -- 00:00:57.269 in our earnings release issued today, and statements containing projections regarding 00:00:57.269 -- 00:01:02.474 future events or our future financial or operational results and performance, 00:01:02.474 -- 00:01:08.100 including our anticipated 2025 total revenue, our expectations regarding reimbursement 00:01:08.100 -- 00:01:13.647 for our products, opportunities for growth, the clinical value of our tests, Impacts 00:01:13.647 -- 00:01:18.775 of seasonality and other trends, the timing of targeted milestones, ou...